RecruitingPhase 1NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Sponsor: Eli Lilly and Company
Indianapolis, IN · +22 more sites
Breast Cancer clinical trials in Indianapolis, IN
18 recruiting breast cancer studies with a site in Indianapolis, IN.
RecruitingPhase 3NCT07391774
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Sponsor: National Cancer Institute (NCI)
Avon, IN · Carmel, IN · Indianapolis, IN · +200 more sites
RecruitingPhase 3NCT07174336
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Sponsor: Eli Lilly and Company
Indianapolis, IN · Newburgh, IN · +126 more sites
RecruitingPhase 3NCT06982521
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Sponsor: Relay Therapeutics, Inc.
Indianapolis, IN · +51 more sites
RecruitingPhase 2NCT05557877
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
Sponsor: Mayo Clinic
Indianapolis, IN · +4 more sites
RecruitingNot applicableNCT07214532
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Sponsor: Natera, Inc.
Dyer, IN · Indianapolis, IN · +47 more sites
RecruitingPhase 1 / Phase 2NCT07488676
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Sponsor: Astellas Pharma Global Development, Inc.
Indianapolis, IN · +17 more sites
RecruitingPhase 2NCT05846789
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Sponsor: Kathy Miller
Carmel, IN · Indianapolis, IN · +4 more sites
RecruitingPhase 3NCT05879926
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor: NRG Oncology
Avon, IN · Carmel, IN · Crown Point, IN · +1223 more sites
RecruitingPhase 1NCT06949410
HER2 Vaccine for Locally Advanced Breast Cancer
Sponsor: Pravin T.P Kaumaya
Indianapolis, IN
RecruitingPhase 3NCT05812807
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Sponsor: Alliance for Clinical Trials in Oncology
Avon, IN · Carmel, IN · Crown Point, IN · +825 more sites
RecruitingPhase 1NCT04389632
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Crown Point, IN · Fort Wayne, IN · Indianapolis, IN · +103 more sites
RecruitingPhase 1NCT07046923
A Study of LY4175408 in Participants With Advanced Cancer
Sponsor: Eli Lilly and Company
Indianapolis, IN · +14 more sites
RecruitingPhase 3NCT04852887
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Sponsor: NRG Oncology
Avon, IN · Carmel, IN · Crown Point, IN · +809 more sites
RecruitingPhase 1 / Phase 2NCT06956690
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Sponsor: Hummingbird Bioscience
Indianapolis, IN · +4 more sites
RecruitingNot applicableNCT06744465
NearWave Optical Molecular Monitoring
Sponsor: Indiana University
Indianapolis, IN
RecruitingPhase 3NCT05929768
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Sponsor: SWOG Cancer Research Network
Avon, IN · Carmel, IN · Crown Point, IN · +952 more sites
RecruitingPhase 1NCT05216432
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Sponsor: Relay Therapeutics, Inc.
Indianapolis, IN · +23 more sites
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.